We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

NGS Technology-Based Assay Detects Minimal Residual Disease in Patients with Lymphatic Hematological Tumors

By LabMedica International staff writers
Posted on 20 Apr 2022
Image: Genetron has received CE Mark for its human B lymphocyte minimal residual disease detection kit (Photo courtesy of Genetron Health)
Image: Genetron has received CE Mark for its human B lymphocyte minimal residual disease detection kit (Photo courtesy of Genetron Health)

A new assay based on high-throughput next generation sequencing (NGS) technology can test the CDR3 regional sequence of the IgH/K/L gene of the B cell receptor (BCR) in bone marrow samples collected from patients with B lymphpocytic leukemia (B-ALL/CLL) and multiple myeloma (MM) before and after the treatment. By screening out significant and specific clonal rearrangement form in a patient's tumor cells, this approach can detect minimal residual disease and provide a reference for the follow-up treatment of cancer survivors.

Genetron Health’s (Beijing, China) proprietary Human B Lymphocyte Minimal Residual Disease Detection Kit (Reversible Termination Sequencing Method), which is also known as Seq-MRD, has been optimized with the company’s “One-step Seq Method” technology, which enables the DNA library construction process for gene sequencing to finish with a single PCR and minimizes the risks of sample contamination and false positive results. This simple operational feature, combined with the company’s automated bioinformatics analysis solution, enables Seq-MRD to have broad application prospects due to its key technological advantages of high throughput, fast turnaround, stability and accuracy, and high cost-efficiency.

Recently, an experiment was completed that identified the assay performance in various perspectives, such as sensitivity, accuracy, specificity and precision, among which, 128 clinically confirmed samples showed a high concordance on positive detection results from the Seq-MRD assay and the traditional technology of flow cytometry (FCM). More importantly, there were 10 samples detected as positive by Seq-MRD assay, which were identified as negative by FCM, demonstrating the higher sensitivity of the assay. Seq-MRD has received a CE Mark, allowing it to be distributed throughout the EU countries as well as the UK.

Related Links:
Genetron Health 

Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Rapid Molecular Testing Device
FlashDetect Flash10
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay

Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more